Tuesday, October 18, 2011
Infinity Pharmaceuticals Inc., of Cambridge, Mass., completed enrollment in a Phase II trial of IPI-926 for pancreatic cancer. The trial has enrolled 122 patients and will compare IPI-926 in combination with gemcitabine to placebo and gemcitabine with a primary endpoint of overall survival.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.